These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34331192)

  • 1. Aerosol delivery systems for treating obstructive airway diseases during the SARS-CoV-2 pandemic.
    Lavorini F; Usmani OS; Dhand R
    Intern Emerg Med; 2021 Nov; 16(8):2035-2039. PubMed ID: 34331192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aerosol therapy].
    Wildhaber JH
    Schweiz Med Wochenschr; 1998 Aug; 128(33):1223-8. PubMed ID: 9757487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of nebulized pharmacotherapies during the COVID-19 pandemic.
    Sethi S; Barjaktarevic IZ; Tashkin DP
    Ther Adv Respir Dis; 2020; 14():1753466620954366. PubMed ID: 33167796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19.
    Ari A
    Respir Med; 2020 Jun; 167():105987. PubMed ID: 32421541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaler and spacer use in obstructive airway diseases.
    Jones MD; Yeager H
    Am Fam Physician; 1990 Oct; 42(4):1007-13. PubMed ID: 2220509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based treatment during the SARS-CoV-2 pandemic: Identifying the knowns and unknowns of nebulization.
    Woods JA
    J Am Pharm Assoc (2003); 2021; 61(2):e55-e56. PubMed ID: 33160867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deposition distribution of the new coronavirus (SARS-CoV-2) in the human airways upon exposure to cough-generated droplets and aerosol particles.
    Madas BG; Füri P; Farkas Á; Nagy A; Czitrovszky A; Balásházy I; Schay GG; Horváth A
    Sci Rep; 2020 Dec; 10(1):22430. PubMed ID: 33384436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.
    Lavorini F; Mannini C; Chellini E; Fontana GA
    Drugs Aging; 2016 Jul; 33(7):461-73. PubMed ID: 27216613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance on nebulization during the current COVID-19 pandemic.
    Cazzola M; Ora J; Bianco A; Rogliani P; Matera MG
    Respir Med; 2021 Jan; 176():106236. PubMed ID: 33248363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Airborne transmission of SARS-CoV-2 is the dominant route of transmission: droplets and aerosols.
    Rabaan AA; Al-Ahmed SH; Al-Malkey M; Alsubki R; Ezzikouri S; Al-Hababi FH; Sah R; Al Mutair A; Alhumaid S; Al-Tawfiq JA; Al-Omari A; Al-Qaaneh AM; Al-Qahtani M; Tirupathi R; Al Hamad MA; Al-Baghli NA; Sulaiman T; Alsubait A; Mehta R; Abass E; Alawi M; Alshahrani F; Shrestha DB; Karobari MI; Pecho-Silva S; Arteaga-Livias K; Bonilla-Aldana DK; Rodriguez-Morales AJ
    Infez Med; 2021 Mar; 29(1):10-19. PubMed ID: 33664169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home.
    Ari A; Blain K; Soubra S; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2687-2695. PubMed ID: 34611397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosol transmission of SARS-CoV-2 by children and adults during the COVID-19 pandemic.
    Moschovis PP; Yonker LM; Shah J; Singh D; Demokritou P; Kinane TB
    Pediatr Pulmonol; 2021 Jun; 56(6):1389-1394. PubMed ID: 33624927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aerosol Delivery Devices for Obstructive Lung Diseases.
    Pleasants RA; Hess DR
    Respir Care; 2018 Jun; 63(6):708-733. PubMed ID: 29794206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROMOTING SAFE AND EFFECTIVE USE OF AEROSOL DEVICES IN COVID-19:RISKS AND SUGGESTIONS FOR VIRAL TRANSMISSION.
    Ari A
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1509-1513. PubMed ID: 32799579
    [No Abstract]   [Full Text] [Related]  

  • 16. Changing delivery methods for obstructive lung diseases.
    Dolovich M
    Curr Opin Pulm Med; 1997 May; 3(3):177-89. PubMed ID: 9232363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An
    Mac Giolla Eain M; Joyce M; MacLoughlin R
    Drug Deliv; 2021 Dec; 28(1):1496-1500. PubMed ID: 34259091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Microbial Risk Assessment for Airborne Transmission of SARS-CoV-2 via Breathing, Speaking, Singing, Coughing, and Sneezing.
    Schijven J; Vermeulen LC; Swart A; Meijer A; Duizer E; de Roda Husman AM
    Environ Health Perspect; 2021 Apr; 129(4):47002. PubMed ID: 33793301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of inhalation of a glucocorticoid using metered-dose propellant gas aerosol and Turbohaler--a roentgen pilot study].
    Vogel H; Wettmarshausen C
    Pneumologie; 1995 Oct; 49(10):559-60. PubMed ID: 8584527
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective inhaled drug administration to mechanically ventilated patients.
    Dhand R; Mercier E
    Expert Opin Drug Deliv; 2007 Jan; 4(1):47-61. PubMed ID: 17184162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.